VisionApp test for ghosting in single-eye (monocular) vision
Official title: Assessment of the Accuracy and Repeatability of the VisionApp - Ghosting Measurement Protocol
Run by Indiana University · NCT07571538 · Data updated 2026-11-12
This test tries the VisionApp smartphone app to see if it can accurately measure ghosting in people with monocular diplopia.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 8 Years and up |
| Sex | All |
| Enrollment | 12 (estimated) |
| Sponsor | Indiana University Academic / other |
| Locations | 1 site (Bloomington, Indiana) |
| Status | Recruiting |
| Started | October 10, 2025 |
| Main results expected | December 1, 2026 |
| Study ends | December 1, 2026 |
| Registry record updated | August 24, 2026 |
| Trial ID | NCT07571538 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
People (adults and children) with plano to -5.00 D refractive error, ≤ -0.75 D astigmatism, recent eye exam, best-corrected visual acuity of 20/20 in each eye, no amblyopia or diagnosed ocular disease, and ability to follow the visit schedule are ideal candidates.
✕Probably not a fit
Patients with significant ocular disease, amblyopia, high refractive errors or astigmatism beyond the eligibility limits, systemic conditions or medications affecting vision, or those unable to attend an in-person visit are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will compare VisionApp measurements to standard clinical tests by having participants complete refraction, visual acuity checks, and lighting controls at the Clinical Optics Research Lab. Participants will wear a single-vision contact lens in one eye and two different multifocal lenses in the other eye while reporting perceived shadows or distortions using slider bars and numerical ratings. The protocol includes both adults and children with age-appropriate multifocal lenses and uses randomization to determine lens order. The study will analyze accuracy, repeatability, and reproducibility of the app-based ghosting measurements across sessions.
Why it matters
Potential benefit: If successful, this could provide a low-cost, easy way to measure and monitor ghosting that helps clinicians and patients choose and compare contact lens options.
How similar studies have gone: Some smartphone refraction tools have shown promising accuracy for measuring refractive error, but using an app specifically to quantify ghosting in monocular diplopia is relatively novel and less validated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * has a refractive error between Plano and -5.00 D of sphere and cylinder components combined. * has refractive cylinder (e.g., astigmatism) of -0.75 D or less * has had a self-reported oculo-visual exam in the last 2 years * has best-corrected visual acuity of at least 20/20 in each eye * is not amblyopic or does not have any diagnosed ocular disease * is willing and able to follow instructions and maintain the appointment schedule Exclusion Criteria: * has any systemic disease affecting ocular health and visual acuity * is currently using any systemic or topical medications that could affect ocular health and visual acuity * is participating in another eye related research study
Where it's running
-
Clinical Optics Research Lab
Bloomington, Indiana, United States Recruiting
Study contacts
- Study coordinator: Pete Kollbaum, PhD
- Email: kollbaum@iu.edu
- Phone: 812-555-5500
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Goal setting in a school-based sport program for rural middle schoolers
This project tests whether a 6-week goal-setting program embedded in a school sport program can boost physical activity among 6th–7th graders in two rural Indiana middle schools.
-
Eye drops Rhopressa vs Timolol to protect nerve cells in glaucoma
In adults with open-angle glaucoma, this study tests whether Rhopressa helps preserve retinal nerve cells better than Timolol while both lower eye pressure.
-
Hydroxychloroquine for AIMSS in breast cancer patients on aromatase inhibitors
This study tests whether hydroxychloroquine can reduce joint pain in people with breast cancer who are taking aromatase inhibitors and have AIMSS.
-
New ways to diagnose lymphoma and multicentric Castleman disease in people living with HIV
This study tests a quick, point-of-care nucleic acid test to help diagnose lymphoma and multicentric Castleman disease in people living with HIV in sub-Saharan Africa.
-
Sensor-enabled ankle brace for gait and balance testing in adults
Researchers are testing a modified ankle brace with built-in sensors to see if it accurately measures gait and balance compared with standard equipment in healthy adults.
-
Radiation-related heart damage in locally advanced NSCLC tested with PET-CT
This study tests whether PET-CT imaging with 18F-Flurpiridaz can detect early radiation-related heart damage in adults with locally advanced non-small cell lung cancer receiving standard chemoradiation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.